Business Context and Reporting Period
This Form 8-K Current Report is filed by AnaptysBio, Inc. (Nasdaq: ANAB) for the reporting period of May 11, 2026. The filing discloses significant corporate governance changes, specifically the appointment of a new Chief Financial Officer and a new member to the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and board appointments.
Material Changes and Appointments
Appointment of Chief Financial Officer
Effective May 11, 2026, the Board appointed Christopher M. Murphy as Chief Financial Officer. Mr. Murphy joins as an independent contractor under a consulting agreement with the following terms:
- Compensation: Monthly consulting fees of $42,916.66.
- Bonus: Annual target cash bonus opportunity of up to 40% of total annual consulting fees, based on performance goals.
- Equity: An initial grant of Restricted Stock Units (RSUs) valued at $1,750,000.
- Vesting Schedule: 25% vests on the first anniversary of the effective date; the remaining 75% vests in equal annual installments over the subsequent three years.
- Termination Provisions:
- Without Cause (General): 9 months of continued consulting fees upon waiver and release.
- Without Cause (Corporate Transaction): 12 months of continued fees, a lump-sum cash amount (including prorated bonus), and full acceleration of all outstanding equity awards.
Appointment of Director
Effective May 11, 2026, the Board appointed Owen Hughes as a Class I non-employee director.
- Equity Grant: Received an initial grant of 11,250 RSUs.
- Vesting: Vests over a three-year period subject to continued service.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of material risks and contingencies. The document notes that the full text of the Murphy Consulting Agreement will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2026.
Investor Verification Checklist
- Verify the total annualized cash compensation for the new CFO ($42,916.66 x 12 = $515,000) plus potential bonus.
- Confirm the current share price to validate the $1,750,000 valuation of the CFO's RSU grant.
- Review the upcoming Form 10-Q (due after June 30, 2026) for the full text of the Murphy Consulting Agreement.
- Assess the impact of the new CFO's background (Third Harmonic Bio, Horizon Therapeutics) on the company's strategic direction.
- Monitor the vesting schedule of the new director's 11,250 RSUs.